Efficacy and drug interactions of the new HMG‐CoA reductase inhibitors cerivastatin and atorvastatin in CsA‐treated renal transplant recipients.

Background. Hyperlipidaemia is an important risk factor for cardiovascular disease in renal transplant recipients. The aim of this study was to test the efficacy and possible drug–drug interactions of the new HMG‐CoA reductase inhibitors (statins) atorvastatin and cerivastatin in cyclosporin A (CsA)‐treated renal transplant patients. [ABSTRACT FROM PUBLISHER]